超级肥胖患者万古霉素给药:少即是多
该研究基于346例肥胖及超级肥胖成人的万古霉素常规峰谷浓度监测数据,建立群体药代动力学模型并采用蒙特卡洛模拟制定经验给药诺模图。结果显示,维持剂量超过4500 mg/天在临床相关清除率下无必要达到药效学AUC目标,提示基于标准肌酐和AUC导向TDM的个体化给药可优化治疗。
要点
- 肥胖及超级肥胖成人经验万古霉素剂量无需超过4500 mg/天即可达AUC目标。
- 万古霉素清除率与年龄、血清肌酐、性别及异速缩放体重呈线性组合。
- 基于标准肌酐和AUC导向TDM的个体化给药可优化肥胖患者治疗。
核心结论
- 基于常见临床变量(含标准化肌酐)的经验给药联合AUC导向TDM可优化肥胖及超级肥胖成人的万古霉素治疗。
研究设计与样本
- 群体药代动力学研究,纳入346例肥胖及超级肥胖成人,利用常规峰谷浓度TDM数据建模,并通过蒙特卡洛模拟制定经验给药诺模图。
主要发现
- 共纳入346例患者,体重范围69.6-293.6 kg,BMI范围30.1-85.7 kg/m2。
- 最终模型中万古霉素清除率由年龄、血清肌酐、性别及异速缩放体重的线性组合描述。
- 蒙特卡洛模拟显示,在临床相关清除率值下,肥胖及超级肥胖患者无需维持剂量>4500 mg/天即可达到药效学AUC目标。
关键数值与推荐
- 经验维持剂量>4500 mg/天在临床相关万古霉素清除率下不必要达到药效学AUC目标。
临床怎么用
- 对肥胖及超级肥胖成人,可基于年龄、标准化血清肌酐、性别和异速缩放体重进行经验万古霉素给药,并后续采用AUC导向TDM个体化调整。
局限性
- 研究基于常规TDM数据,未报告对急性肾损伤概率的具体量化结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vancomycin remains the mainstay of empirical therapy directed against MRSA. National guidelines recommend empirical dosing based on total body weight with trough-level therapeutic drug monitoring (TDM), which may not be optimal in obese and super obese patients. Furthermore, nomograms for empirical vancomycin dosing by estimated kidney function pre-date standardization of creatinine assays. OBJECTIVES: To determine an empirical vancomycin dosing strategy for obese and super obese adults that is consistent with the AUC monitoring paradigm. METHODS: We conducted a population pharmacokinetic study using data obtained from routine peak and trough TDM of vancomycin in obese and super obese adults. An empirical dosing nomogram was developed using Monte Carlo simulation to identify vancomycin doses that optimize the probability of efficacy and minimize the probability of acute kidney injury based on AUC. RESULTS: A total of 346 patients were included encompassing a wide range of body weight (69.6-293.6 kg) and BMI (30.1-85.7 kg/m2) values. In the final model, vancomycin clearance (CLV) was described using a linear combination of age, serum creatinine, sex and allometrically scaled body weight. Monte Carlo simulation demonstrated that maintenance doses >4500 mg/day were not required to achieve pharmacodynamic AUC targets in obese and super obese patients at clinically relevant values of CLV. CONCLUSIONS: Empirical vancomycin dosing informed by common clinical variables, including standardized creatinine, with subsequent individualization using AUC-targeted TDM can optimize therapy in obese and super obese adults.
引用
- Crass RL, Dunn R, Hong J, et al. Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother. 2018. PMID: 30203073. doi:10.1093/jac/dky310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。